

PRESS RELEASE

Syngene Results Q4 FY26 and full-year FY26

**Full-year revenue from operations up 3% to Rs. 3,739 Cr
Fourth quarter revenue from operations up 2% year-on-year to Rs. 1,037 Cr**

Fourth quarter performance:

- Revenue from operations was up 2% year-on-year to Rs. 1,037 Cr and up 13% quarter-on-quarter
- Operating EBITDA margin at 29%
- Profit after tax, before exceptional items, was Rs. 153 Cr

Full year performance:

- Revenue from operations up 3% year-on-year to Rs. 3,739 Cr
- Operating EBITDA margin at 25%
- Profit after tax, before exceptional items, was Rs. 380 Cr
- Net cash generated during the year was Rs. 521 Cr

Bengaluru, April 29, 2026: Syngene International Limited today announced its fourth quarter and full-year results for FY26.

Quarterly Financial Highlights (All numbers are in Indian rupees in Crores except margins)

	Q4 FY25	Q4 FY26	YoY Change (%)
Revenue from Operations	1,018	1,037	2%
Operating EBITDA	344	303	-12%
Operating EBITDA margin (%)	34%	29%	
PAT (before exceptional items)	183	153 ¹	-16%
PAT Margin (%) (before exceptional items)	18%	14%	

Q4 FY26 Reported PAT after exceptional items was Rs. 148 Cr.

1. Excludes (i) a gratuity re-measurement credit of Rs. 20 Cr (net of tax) arising from revised labour codes, and (ii) expenses of Rs 25 Cr (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.

FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins)

	FY25	FY26	YoY Change (%)
Revenue from Operations	3,642	3,739	3%
Operating EBITDA	1,042	918	-12%
Operating EBITDA margin (%)	29%	25%	
PAT (before exceptional items)	475 ²	380 ³	-20%
PAT Margin (%) (before exceptional items)	13%	10%	

FY26 Reported PAT after exceptional items was Rs. 317 Cr.

2. Excludes an exceptional item of Rs 21 Cr (net of tax) relating to the final settlement from an insurance claim. Reported PAT after exceptional items was Rs. 496 Cr.

3. Excludes (i) impact of Rs. 38 Cr (net of tax) pertaining to the net increase in gratuity liabilities on account of newly implemented labour codes, and (ii) expenses of Rs 25 Cr (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.

Syngene International Limited Executive Chairperson, Kiran Mazumdar-Shaw, said, *“I am pleased to take on the role of Executive Chairperson at Syngene at a pivotal moment in its growth journey. I look forward to working with the new leadership team to shape our next phase of expansion, as we continue to benefit from the rising global demand for outsourcing across the life sciences sector. While biotech funding remains discerning and largely concentrated on late-stage assets, Syngene’s diversified end-to-end business model—from discovery and development to manufacturing gives us both resilience and strategic agility in navigating these market realities. We are also focused on building new business lines, strengthening our differentiated service offerings, and investing in AI and digital capabilities that will enhance speed, productivity, and value creation for our clients.”*

Peter Bains, Managing Director and CEO, Syngene International Limited, said, *“Syngene’s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance. The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. During the year, we continued to invest in new capabilities and emerging modalities such as peptides and ADCs, further strengthening our integrated offering and positioning us for long-term growth.”*

Deepak Jain, Chief Financial Officer, Syngene International Limited, said, *“Q4 reported growth at 2% and 13% sequentially reflects the ongoing product impact in our largest biologics customer, resulting in full year growth of 3%. Operating EBITDA margin at 25% for the year reflects this impact and additional operating costs as we bring the new biologics manufacturing facility in India into operations. We generated Rs. 521 Cr of cash during the year, post capex investment, strengthening our balance sheet.”*

For fiscal year 2026, the Board of Directors has recommended a final dividend of Rs.1.25 per share, subject to shareholders approval.

Key Board and Management Changes:

- **Ms. Kiran Mazumdar-Shaw** has transitioned from Non-Executive Chairperson to **Executive Chairperson**, effective April 1, 2026, for a five-year term.
- **Mr. Siddharth Mittal** has been appointed **Managing Director and Chief Executive Officer**, effective July 1, 2026, for a five-year term, succeeding Peter Bains. Siddharth joins from Biocon Limited, where he served as Managing Director and CEO.
- Board has recommended the appointment of **Mr. Vijaya Chandru and Mr. Arun Chandavarkar** as independent directors from the conclusion of 33rd Annual General Meeting.
- Reappointment of **Ms. Vinita Bali** as additional non-executive director for a further period of one-year from July 22, 2026, to July 21, 2027.
- **Ms. Maninder Kapoor Puri** joins Syngene as **Chief Human Resources Officer** and a member of the Executive Committee, effective May 1, 2026. She previously led the human resources function at Biocon.
- **Mr. Abhijit Zutshi** joins Syngene as **Chief Commercial Officer** and a member of the Executive Committee, effective May 1, 2026. He previously served as Chief Commercial Officer at Biocon.

Key Quarterly Business Highlights:

- **Expansion in Antibody-Drug Conjugates (ADCs):** Syngene is building end-to-end capabilities across the Antibody-Drug Conjugate (ADC) value chain as part of its proactive strategy to invest in high-growth novel modalities. Building on the addition of a GMP bioconjugation suite earlier this year, the company commenced operations at its ADC discovery laboratory during the quarter. This facility is equipped to handle highly potent compounds and supports high-throughput experimentation, completing an integrated platform that supports clients from discovery through to manufacturing.
- **Quality and Regulatory Audits:** Syngene completed 14 client and regulatory audits during the quarter, bringing the full-year total to 85. Syngene obtained Good Clinical Practice – National Accreditation Board for Testing and Calibration Laboratories (GCP-NABL) accreditation during the quarter, reinforcing adherence to globally recognized standards for clinical research and data quality.
- **Sustainability and ESG:** Syngene earned a place in the prestigious S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies and the top 9% globally. The company was also recognized as an ‘Industry Mover’ for achieving the highest year-on-year improvement in its Corporate Sustainability Assessment score.

Earnings Call: Syngene will host an investor call at 2 pm IST on April 30, 2026, where the senior management will discuss the Company’s performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1279 / +91 22 7115 8180. Participants can also join the call via this webcast [link](#). Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available until May 07, 2026, on 91 22 71945757, Playback ID: 78075#. We will aim to post the transcript of the conference call on the company website within seven working days of the investor conference call.

About Syngene: Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s team of over 8,300 employees including 5,700+ scientists, brings both deep expertise and the capacity to deliver scientific excellence, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With over 3 Mn sq. ft of specialized discovery, development, and manufacturing facilities across India and the U.S., Syngene works with ~400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis, and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company’s latest Environmental, Social, and Governance (ESG) report, visit [Syngene ESG Report](#).

Contact details:

Media Contact	Investor Contact
Vijay Jeevanandham E: Vijay.jeevanandham@syngeneintl.com	Nandini Agarwal E: Nandini.agarwal@syngeneintl.com

Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management’s current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance

and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.